Eur Respir J 2001; 17:1070-1077
Copyright ©ERS Journals Ltd 2001
Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells
S.H. Korn,
A. Jerre and
R. Brattsand
Inflammatory Pharmacology, AstraZeneca, Lund, Sweden
CORRESPONDENCE: R. Bratts and AstraZeneca R&D Operations, S-22187, Lund, Sweden. Fax: 46 46336624
Keywords: budesonide, ß2-agonist and glucocorticoid interactions, formoterol, granulocyte macrophage-colony stimulating factor, interleukin-8, triggered bronchial epithelial cells
Received: August 24, 2000
Accepted March 19, 2001
The effect of formoterol, alone and in combination with budesonide, upon tumour necrosis factor- stimulated (10 ng·mL1) human bronchial epithelial cells was investigated.
Addition of formoterol ( 1010 M) reduced granulocyte macrophage-colony stimulating factor (GM-CSF) levels, as assessed by enzyme-linked immunosorbent assay, by 4050% and increased interleukin (IL)-8 levels by 50%. The effects of formoterol were long lasting (23 h). Budesonide (108 M) reduced the amounts of both cytokines (GM-CSF and IL-8) by 40%. Simultaneous addition of formoterol and budesonide reduced GM-CSF levels 75%, while IL-8 levels were decreased 40%, similar to the reduction obtained with budesonide alone. The glucocorticoid receptor (GR) antagonist RU486 did not influence the effect of formoterol, suggesting no involvement of the GR. Formoterol rapidly induced an elevation in intracellular cyclic adenosine monophosphate, which was reduced in the presence of propranolol. In addition, the alterations in cytokine secretion induced by formoterol could be fully blocked by propranolol, demonstrating that these effects are ß2-receptor mediated.
In conclusion, the combination of budesonide and formoterol reduces the secretion of granulocyte macrophage-colony stimulating factor to basal levels and counteracts the capacity of formoterol alone to induce interleukin-8 production, modulations which may facilitate improved asthma control.
This article has been cited by other articles:

|
 |

|
 |
 
C-H. Hung, Y-T. Chu, Y-M. Hua, S-H. Hsu, C-S. Lin, H-C. Chang, M-S. Lee, and Y-J. Jong
Effects of formoterol and salmeterol on the production of Th1- and Th2-related chemokines by monocytes and bronchial epithelial cells
Eur. Respir. J.,
June 1, 2008;
31(6):
1313 - 1321.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. R. Washko, V. S. Fan, S. D. Ramsey, Z. Mohsenifar, F. Martinez, B. J. Make, F. C. Sciurba, G. J. Criner, O. Minai, M. M. DeCamp, et al.
The Effect of Lung Volume Reduction Surgery on Chronic Obstructive Pulmonary Disease Exacerbations
Am. J. Respir. Crit. Care Med.,
January 15, 2008;
177(2):
164 - 169.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kaur, J. E. Chivers, M. A. Giembycz, and R. Newton
Long-Acting 2-Adrenoceptor Agonists Synergistically Enhance Glucocorticoid-Dependent Transcription in Human Airway Epithelial and Smooth Muscle Cells
Mol. Pharmacol.,
January 1, 2008;
73(1):
203 - 214.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Loven, N. Svitacheva, A. Jerre, A. Miller-Larsson, and S. H. Korn
Anti-inflammatory activity of {beta}2-agonists in primary lung epithelial cells is independent of glucocorticoid receptor
Eur. Respir. J.,
November 1, 2007;
30(5):
848 - 856.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Suissa, R. McGhan, D. Niewoehner, and B. Make
Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS,
October 1, 2007;
4(7):
535 - 542.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Edwards, J. Haas, R. A. Panettieri Jr., M. Johnson, and S. L. Johnston
Corticosteroids and beta2 Agonists Differentially Regulate Rhinovirus-induced Interleukin-6 via Distinct Cis-acting Elements
J. Biol. Chem.,
May 25, 2007;
282(21):
15366 - 15375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. McCluskie, U. Klein, C. Linnevers, Y.-h. Ji, A. Yang, C. Husfeld, and G. R. Thomas
Phosphodiesterase Type 4 Inhibitors Cause Proinflammatory Effects in Vivo
J. Pharmacol. Exp. Ther.,
October 1, 2006;
319(1):
468 - 476.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Edwards, M. W. Johnson, and S. L. Johnston
Combination Therapy: Synergistic Suppression of Virus-Induced Chemokines in Airway Epithelial Cells
Am. J. Respir. Cell Mol. Biol.,
May 1, 2006;
34(5):
616 - 624.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. N. Chorley, Y. Li, S. Fang, J.-A. Park, and K. B. Adler
(R)-Albuterol Elicits Antiinflammatory Effects in Human Airway Epithelial Cells via iNOS
Am. J. Respir. Cell Mol. Biol.,
January 1, 2006;
34(1):
119 - 127.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. S. Usmani, K. Ito, K. Maneechotesuwan, M. Ito, M. Johnson, P. J. Barnes, and I. M. Adcock
Glucocorticoid Receptor Nuclear Translocation in Airway Cells after Inhaled Combination Therapy
Am. J. Respir. Crit. Care Med.,
September 15, 2005;
172(6):
704 - 712.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M Decramer, R Gosselink, P Bartsch, C-G Lofdahl, W Vincken, R Dekhuijzen, J Vestbo, R Pauwels, R Naeije, and T Troosters
Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004
Thorax,
April 1, 2005;
60(4):
343 - 349.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Linden, M. Laan, and G. P. Anderson
Neutrophils, interleukin-17A and lung disease
Eur. Respir. J.,
January 1, 2005;
25(1):
159 - 172.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Roth, P. R.A. Johnson, P. Borger, M. P. Bihl, J. J. Rudiger, G. G. King, Q. Ge, K. Hostettler, J. K. Burgess, J. L. Black, et al.
Dysfunctional Interaction of C/EBP{alpha} and the Glucocorticoid Receptor in Asthmatic Bronchial Smooth-Muscle Cells
N. Engl. J. Med.,
August 5, 2004;
351(6):
560 - 574.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Miyamoto, M. Tomaki, J. Lotvall, and A. Linden
{beta}-Adrenoceptor stimulation and neutrophil accumulation in mouse airways
Eur. Respir. J.,
August 1, 2004;
24(2):
231 - 237.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Cazzola and R. Dahl
Inhaled Combination Therapy With Long-Acting {beta}2-Agonists and Corticosteroids in Stable COPD
Chest,
July 1, 2004;
126(1):
220 - 237.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Schulz, K. Kratzel, K. Wolf, S. Schroll, M. Kohler, and M. Pfeifer
Activation of Bronchial Epithelial Cells in Smokers Without Airway Obstruction and Patients With COPD
Chest,
May 1, 2004;
125(5):
1706 - 1713.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kunz, R. Sandoval, P. Carlsson, J. Carlstedt-Duke, J. W. Bloom, and R. L. Miesfeld
Identification of a Novel Glucocorticoid Receptor Mutation in Budesonide-Resistant Human Bronchial Epithelial Cells
Mol. Endocrinol.,
December 1, 2003;
17(12):
2566 - 2582.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D.W. Reid, C. Ward, N. Wang, L. Zheng, R. Bish, B. Orsida, and E.H. Walters
Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo
Eur. Respir. J.,
June 1, 2003;
21(6):
994 - 999.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P A Beckett and P H Howarth
Pharmacotherapy and airway remodelling in asthma?
Thorax,
February 1, 2003;
58(2):
163 - 174.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Faisy, E. Naline, J.-L. Diehl, X. Emonds-Alt, T. Chinet, and C. Advenier
In vitro sensitization of human bronchus by beta 2-adrenergic agonists
Am J Physiol Lung Cell Mol Physiol,
November 1, 2002;
283(5):
L1033 - L1042.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P.J. Barnes
Scientific rationale for inhaled combination therapy with long-acting {beta}2-agonists and corticosteroids
Eur. Respir. J.,
January 1, 2002;
19(1):
182 - 191.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A.J. Knox, Y.M. Zhu, and L. Pang
Do long-acting {beta}2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma?
Eur. Respir. J.,
June 1, 2001;
17(6):
1059 - 1061.
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the European Respiratory Society.
|